SCHEMBL6180556

SCHEMBL6180556

CCOC(=O)N1C=CC(N)=CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.37
HSD17B10 Q99714 1/20 0.37
LMNA P02545 4/20 0.35
CYP1A2 P05177 3/20 0.35
CYP3A4 P08684 1/20 0.35
MAOA P21397 1/20 0.35
KDM4E B2RXH2 4/20 0.35
TSHR P16473 2/20 0.34
GSK3A P49840 1/20 0.34
GSK3B P49841 1/20 0.34
MAPT P10636 4/20 0.33
POLB P06746 2/20 0.33
ABL1 P00519 1/20 0.33
RIN1 Q13671 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
GAA P10253 3/20 0.33
LPO P22079 2/20 0.33
HPGD P15428 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28369881 0.83 P2RX4 (0.32) ALDH1A1HSD17B10
SCHEMBL27672566 0.81 ALDH1A1 (0.36) ALDH1A1LMNAKDM4ETSHRGSK3A
SCHEMBL15390474 0.79 NR1H2 (0.39) KDM4EMAPTPOLBSMN1; SMN2
SCHEMBL4771331 0.68 TSHR (0.35) ALDH1A1HSD17B10LMNACYP1A2KDM4E
SCHEMBL10654652 0.68 SMN1; SMN2 (0.56) ALDH1A1LMNAKDM4ETSHRGSK3A
Hydrochloric Acid SCHEMBL4774116 0.67 TSHR (0.34) ALDH1A1HSD17B10LMNACYP1A2KDM4E
SCHEMBL22235641 0.66 HRH1 (0.36) ALDH1A1HSD17B10LMNAKDM4EGSK3A
SCHEMBL6266372 0.65 TSHR (0.37) ALDH1A1HSD17B10LMNAKDM4ETSHR
SCHEMBL4553516 0.64 ALDH1A1 (0.37) ALDH1A1HSD17B10LMNACYP1A2CYP3A4
SCHEMBL29493251 0.64 HDAC3 (0.41) ALDH1A1LMNAKDM4ETSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1123931-B1 Tricylic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases SCHERING CORP (US) 2005-06-01 EP disclosed
US-20030055065-A1 Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases BISHOP W ROBERT (US) 2003-03-20 US disclosed
US-20020068742-A1 Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases BISHOP W ROBERT (US) 2002-06-06 US disclosed
US-6365588-B1 AS ANTINEOPLASTIC AGENT AND A POTENTIATING SCHERING CORPORATION 2002-04-02 US disclosed
EP-1123931-A1 Tricylic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases SCHERING CORPORATION (US) 2001-08-16 EP disclosed
US-6242458-B1 INHIBITING FARNESYL PROTEIN TRANSFERASE IN A HUMAN SCHERING CORPORATION 2001-06-05 US disclosed
US-5807852-A Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases SCHERING CORPORATION (US) 1998-09-15 US disclosed
US-5807853-A Tricyclic amide and urea compounds, useful inhibition of g-protein function and for treatment of proliferative diseases SCHERING CORPORATION (US) 1998-09-15 US disclosed
US-5719148-A FARNESYL-PROTEIN TRANSFERASE INHIBITORS SCHERING CORPORATION (US) 1998-02-17 US disclosed
US-5714609-A FORMING CHEMICAL INTERMEDIATE BY NITRATING SUBSTITUTED BENZO/5,6/CYCLOHEPTA/1,2-B/PYRIDINE WITH TETRABUTYLAMMONIUM NITRATE AND TRIFLUOROACETIC ANHYDRIDE IN SOLVENT AT REDUCED TEMPERATURE SCHERING CORPORATION (US) 1998-02-03 US disclosed
US-5700806-A FARNESYL PROTEIN TRANSFERASE ENZYME INHIBITOR, ANTITUMOR AGENTS SCHERING CORPORATION (US) 1997-12-23 US disclosed
US-5696121-A 4-(3-BROMO 8-CHLORO-6,11-DIHYDRO-5H-BENZO(5,6)CYCLOHEPTA(1,2B)PYRIDINE-11-YL)-N-(3 -PYRIDINYL)-1-PIPERAZINECARBOXIDE; ANTITUMOR AGENT; FARNESYL PROTEIN TRANSFERASE INHIBITOR SCHERING CORPORATION (US) 1997-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055065-A1 Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases RASGRP1, CCNA1, CCNA2 ALDH1A1 3267/4885HSD17B10 4083/4885LMNA 3835/4885
US-20020068742-A1 Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases RASGRP1, CCNA1, CCNA2 ALDH1A1 3267/4885HSD17B10 4083/4885LMNA 3835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.